Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammasome-Targeted Therapy Development.
As the innate immune landscape evolves beyond the crowded NLRP3 space, AIM2 (Absent in Melanoma 2) emerges as a critical cytosolic DNA sensor driving pathological inflammation in autoimmune disorders, sterile inflammatory diseases, and select oncology indications. The transition from broad-spectrum inflammasome inhibition to AIM2-selective modulation requires sophisticated intracellular assays and high-fidelity protein reagents that distinguish PYD-domain interactions from HIN200-DNA binding mechanisms.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AIM2 inflammasome drug discovery:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AIM2 Recombinant Protein (Full-Length, PYD Domain, HIN-200 Domain). High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 expressed. | View AIM2 Products |
| Gene Delivery | AIM2 Lentivirus Premade Particles. Full-length ORF for stable THP-1/HEK293 cell line construction. Endotoxin controlled. | View AIM2 Products |
| Binding Partner | ASC (PYCARD) Recombinant Protein. Critical for AIM2 inflammasome oligomerization assays. High purity (>95%). | View PYCARD Products |
| Counter-Screen | NLRP3 Recombinant Protein. Specificity control for NLR family selectivity assays. Sequence verified. | View NLRP3 Products |
| Benchmark Ab | Anti-AIM2 Recombinant Antibody. Recombinant positive control for high-throughput screening and Western Blot. | View AIM2 Products |
| Validator | AIM2 siRNA Set (3 unique sequences). For knockdown verification and specificity controls in cell-based assays. | View AIM2 Products |
| Related Target | Caspase-1 (CASP1). Downstream executioner protease essential for pyroptosis and IL-1β maturation assays. | View CASP1 Products |
| Related Target | IL-1β (IL1B). Cytokine readout standard for inflammasome activation quantification. | View IL1B Products |
| Related Target | STING (TMEM173). Cytosolic DNA sensor pathway for cross-talk studies and selectivity controls. | View STING Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Localization & Conformation | Lentivirus particles for stable cell line generation preserving native AIM2 oligomerization states in THP-1 monocytes; sequence-verified for overexpression in HEK293/THP-1. |
| ASC Speck Formation Quantification | Purified AIM2-PYD & ASC recombinant proteins (>95% purity) for in vitro oligomerization kinetic assays. |
| NLR Family Selectivity (Off-target Risk) | Homology panel available: AIM2, NLRP3, NLRC4, IFI16 proteins with distinct domain truncations verified by mass spectrometry. |
| Cross-species Translation (Mouse models) | Human and Mouse AIM2 ortholog proteins available; species-specific PYD domain sequences verified. |
| Endotoxin Interference in Immune Assays | Strict Endotoxin Control (<1.0 EU/μg) to prevent false-positive inflammasome activation. |
| Lack of Standardized Assay Controls | Recombinant positive control antibodies and validated siRNA included for specificity checks. |
Live AIM2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Inhibitor Research
- Autoimmune Disease Mechanisms
- Recent Patent Filings
- Latest Resistance Research (PubMed)
Global Clinical Landscape & Future Outlook
The race for AIM2 therapeutics is intensifying as the industry shifts from broad immunosuppression to targeted inflammasome modulation. AIM2 specifically acts as a cytosolic double-stranded DNA (dsDNA) sensor. Pathological accumulation of self-DNA in autoimmune disorders (such as SLE, macrophage activation syndrome, and Aicardi-Goutieres syndrome) positions AIM2 as a critical bottleneck. Conversely, in melanoma and colorectal cancer, AIM2 downregulation correlates with immune evasion, making AIM2 agonists a promising approach to induce pyroptosis and convert 'cold' tumors to 'hot' tumors. As first-generation broad anti-inflammatories reveal safety limitations, the next wave of R&D targets highly selective small molecule inhibitors (blocking dsDNA binding or PYD-ASC interactions) and agonists for oncology. Intracellular delivery technologies and domain-selective inhibitors are key to distinguishing PYD-PYD interactions from HIN200-mediated DNA sensing.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Emerging Biotech, Academic Labs | SLE, Psoriasis, Autoinflammatory | ASC oligomerization inhibition assay (Need purified AIM2-PYD + ASC proteins); selectivity vs NLRP3/IFI16 |
| Small Molecule Agonists | Academic / Pharma Spin-offs | Melanoma, CRC (Solid Tumors) | Cell-based Pyroptosis Assay (Need Lentivirus for stable cell lines and pyroptosis markers) |
| Cell-Penetrating Peptides | Early Stage Discovery | Intracellular Inflammation | Cell-based uptake with Lentivirus-stable reporter lines |
| Nucleic Acid Therapeutics (Antisense, siRNA) | Specialized Gene Therapy Firms, Preclinical Pipelines | Rare Autoinflammatory Diseases, Refractory Autoimmune | Knockdown validation (Need sequence-verified siRNA and positive control antibodies) |
| Biologics (Indirect) | IL-1β Blockade Developers | Cryopyrin-Associated Syndromes | Downstream cytokine quantification standards (IL-1β, IL-18) |